193 related articles for article (PubMed ID: 24696723)
1. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.
Peng WX; Kudo M; Fujii T; Teduka K; Naito Z
Int J Clin Exp Pathol; 2014; 7(3):1069-76. PubMed ID: 24696723
[TBL] [Abstract][Full Text] [Related]
2. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells.
Matsuda Y; Hagio M; Seya T; Ishiwata T
Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155
[TBL] [Abstract][Full Text] [Related]
4. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
6. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
7. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
9. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
[TBL] [Abstract][Full Text] [Related]
10. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
Planagumà J; Díaz-Fuertes M; Gil-Moreno A; Abal M; Monge M; García A; Baró T; Thomson TM; Xercavins J; Alameda F; Reventós J
Cancer Res; 2004 Dec; 64(24):8846-53. PubMed ID: 15604243
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.
Hakim SA; Raboh NM
Int J Clin Exp Pathol; 2015; 8(10):13225-32. PubMed ID: 26722522
[TBL] [Abstract][Full Text] [Related]
13. Mammaglobin B expression in human endometrial cancer.
Tassi RA; Bignotti E; Falchetti M; Calza S; Ravaggi A; Rossi E; Martinelli F; Bandiera E; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2008; 18(5):1090-6. PubMed ID: 18021217
[TBL] [Abstract][Full Text] [Related]
14. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
15. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD
Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093
[TBL] [Abstract][Full Text] [Related]
16. ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.
de Sousa VP; Chaves CB; Huguenin JF; Moreira FC; de Reis BS; Chimelli L; Bergmann A; Simão Tde A; Pinto LF
Cancer Biol Ther; 2014 Jul; 15(7):888-94. PubMed ID: 24756106
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
18. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
20. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]